Clinical Trials Browser

Phase 2 × mirdametinib × Other hematologic neoplasm × Clear all

NCT07061951 2026-04-13

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell